10-Q: Vaxart Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxart, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth driven by government contracts and providing updates on its vaccine development programs.

Summary

• Vaxart, Inc. reported a net loss of $15.59 million, or $0.07 per share, for the three months ended March 31, 2025, compared to a net loss of $24.42 million, or $0.14 per share, for the same period in 2024.
• Total revenue for the first quarter of 2025 was $20.88 million, a significant increase from $2.18 million in the first quarter of 2024, primarily driven by revenue from government contracts.
• Research and development expenses increased to $30.74 million in Q1 2025 from $19.01 million in Q1 2024, due to increased clinical trial expenses for COVID-19 and norovirus vaccine candidates.
• General and administrative expenses decreased to $5.07 million in Q1 2025 from $7.24 million in Q1 2024, mainly due to lower stock-based compensation and professional fees.
• As of March 31, 2025, Vaxart had cash, cash equivalents, and short-term investments totaling $41.9 million.
• The company expects its current cash resources to fund operations into the first quarter of 2026, but will need to raise additional capital to continue as a going concern.
• Vaxart is developing oral recombinant vaccines for norovirus, coronavirus (COVID-19), influenza, and HPV, with ongoing clinical trials and preclinical studies.
• A Phase 1 trial evaluating second-generation oral norovirus vaccine constructs initiated in March 2025, with topline data expected in mid-2025.
• Vaxart is progressing with a Phase 2b study for its oral pill COVID-19 vaccine candidate, supported by funding from HHS BARDA, and has lifted a previous stop work order.
• Phillip Lee, the Chief Financial Officer, has resigned, effective upon the appointment of a new CFO, and Jeroen Grasman has been appointed as the new CFO, effective May 19, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased and the net loss decreased, the company is still operating at a loss and needs to raise additional capital. Progress in clinical trials is positive, but the company faces financial challenges and risks.

Positives

• Revenue increased significantly due to government contracts, indicating successful partnerships and funding.
• The net loss decreased compared to the same period last year, suggesting improved financial management or increased efficiency.
• The company is actively progressing its vaccine pipeline with ongoing clinical trials for norovirus and COVID-19.
• The Lift Notice allows Vaxart to resume work on its COVID-19 vaccine program, maintaining progress in this area.
• The appointment of a new CFO ensures continuity in financial leadership.

Negatives

• The company is still operating at a net loss, indicating that it is not yet profitable.
• The company's cash runway is limited, and it will need to raise additional capital to continue operations.
• Research and development expenses increased, which may strain financial resources.
• The resignation of the CFO creates uncertainty in financial leadership, although a replacement has been named.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• Changes in government funding or contracts could negatively impact revenue and cash flow.
• The company faces competition from other vaccine developers.
• Economic uncertainty, high interest rates, and rising inflation could impact operations and access to capital.

Future Outlook

Vaxart expects to continue advancing its vaccine candidates through clinical trials and pursuing regulatory approvals. The company anticipates needing to raise additional capital to fund its operations beyond the first quarter of 2026. They intend to work with governments around the world to create pandemic monovalent influenza vaccines for emergency use or stockpiling, if requested. They are also continuing development of their preclinical seasonal influenza vaccine candidate.

Industry Context

Vaxart operates in the competitive biotechnology industry, focusing on the development of oral vaccines. The company's progress in clinical trials and partnerships with government agencies positions it to address significant public health needs, such as norovirus, COVID-19, and influenza. The industry is characterized by high research and development costs, regulatory hurdles, and competition from established pharmaceutical companies.

Comparison to Industry Standards

• Vaxart's approach to oral vaccine development differentiates it from many competitors who primarily focus on injectable vaccines, such as Moderna and Pfizer for COVID-19.
• The $460.7 million potential funding from BARDA for the COVID-19 vaccine program is substantial, but contingent on continued progress and government decisions.
• The company's net loss and need for additional capital are common challenges for clinical-stage biotechnology companies, such as Novavax and Inovio Pharmaceuticals, which also require significant funding to advance their pipelines.
• Vaxart's reliance on government contracts for revenue is similar to companies like Emergent BioSolutions, which also derive a significant portion of their revenue from government partnerships.

Management Changes

Legal Proceedings

• The company is involved in legal proceedings, including securities class actions and other lawsuits, which could result in substantial costs and a diversion of management's attention and resources.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by restructuring plans and workforce reductions.
• Customers (potential vaccine recipients) could benefit from successful vaccine development.
• Suppliers and contract manufacturers are impacted by the company's financial condition and research and development activities.
• Creditors face risks related to the company's ability to repay debts.

Next Steps

• Continue discussions with HHS BARDA regarding the plan for dosing participants in the Phase 2b COVID-19 trial.
• Progress with the Phase 1 trial evaluating second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025.
• Seek additional funding through the sale of securities or other means.
• Advance preclinical studies for HPV therapeutic vaccine candidate.
• Work with governments around the world to create pandemic monovalent influenza vaccines for emergency use or stockpiling, if requested.

Key Dates

Keywords

Vaxart, vaccine, COVID-19, norovirus, clinical trial, revenue, financial results, BARDA, oral vaccine, biotechnology